# Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

> **NCT02014844** · PHASE2 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** 250 mg/m2 aldoxorubicin
- **DRUG:** 350 mg/m2 aldoxorubicin

## Key facts

- **NCT ID:** NCT02014844
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02014844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02014844, "Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02014844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*